May 06, 2026

Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis

Caris MI Clarity leverages AI to transform how recurrence risk is understood and applied in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer IRVING, Texas, May 5, 2026 /PRNewswire/ -- Caris Life Sciences®...

recent articles

Do you wonder what the most robust method for segmenting cells and identifying expression in fluorescent imaging is? Explore how our expert Michael Persch, Professional Services Specialist at Visiopharm, designs Deep Learning strategies...

. Join us for this free webinar with a live overview and discussion of the value of a truly integrated digital pathology platform using AI real-time to aid in diagnostic decisions MindPeak and Gestalt partner to provide seamless...

JUNE 23, 2020 | 10 am PDT & 10 am CEST Have you been wondering how to get started with digital tissue analysis? Visiopharm software utilizes an APP based structure, which means that you have all the flexibility you need to design,...

OR

platinum partners

gold partners

Silver Partners

Media Partners